Interestingly, the mRNA-derived vaccine targeting KRAS-mutant peptides (G12D, G12V, G13D and G12C), mRNA-5671/V941, is currently being tested in a combinatory regimen with pembrolizumab in KRAS-mutant NSCLC, PDAC and CRC patients (ClinicalTrials.gov identifier: NCT03948763). The gene discussed is KRAS; the disease is colorectal carcinoma.